NCT05507242View on ClinicalTrials.gov

Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 25, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
COPDCOPD ExacerbationCOPD BronchitisAirway DiseaseImmune System Disorder
Interventions
BIOLOGICAL

Tezepelumab

Tezepelumab 210 mg for 20 weeks (5 doses in total, 4-week intervals), administered subcutaneously

OTHER

Placebo

Placebo subcutaneous injection for 20 weeks (5 doses in total, 4-week intervals)

Trial Locations (2)

2400

RECRUITING

Research site, Copenhagen

LE3 9QP

RECRUITING

Research site, Leicester

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

University Hospitals, Leicester

OTHER

lead

Asger Sverrild

OTHER